Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022
Cancer Research and Treatment · 15.04.2025 · 57 (2) · 312-330
DOI: 10.4143/crt.2025.264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2025. Verfasst von Eun Hye Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Korea Central Cancer Registry, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare, National Cancer Center.
Abstract (Originalsprache)
Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2022, with international comparisons.Materials and Methods Cancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2022), with survival follow-up until December 31, 2023. Mortality data obtained from Statistics Korea, while international comparisons were based on GLOBOCAN data.
Results
In 2022, 282,047 newly diagnosed cancer cases (age-standardized rate [ASR], 287.0 per 100,000) and 83,378 deaths from cancer (ASR, 65.7 per 100,000) were reported. The proportion of localized-stage cancers increased from 45.6% in 2005 to 50.9% in 2022. Stomach, colorectal, and breast cancer showed increased localized-stage diagnoses by 18.1, 18.5, and 9.9 percentage points, respectively. Compared to 2001-2005, the 5-year relative survival (2018-2022) increased by 20.4 percentage points for stomach cancer, 7.6 for colorectal cancer, and 5.6 for breast cancer. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence (M/I) ratios for these cancers. The 5-year relative survival (2018-2022) was 72.9%, contributing to over 2.59 million prevalent cases in 2022.
Conclusion
Since the launch of the National Cancer Screening Program in 2002, early detection has improved, increasing the diagnosis of localized-stage cancers and survival rates. Korea recorded the lowest M/I ratio among major comparison countries, demonstrating the effectiveness of its National Cancer Control Program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Korea Central Cancer Registry, National Cancer Center, Goyang, Korea.
- Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
- National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
- National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Förderung
- Ministry of Health and Welfare
- National Cancer Center
Zitieren
APA
Park, E. H., Jung, K. W., Park, N. J., Kang, M. J., Yun, E. H., Kim, H. J., Kim, J. E., Kong, H. J., Choi, K. S., Yang, H. K., & Community of Population-Based Regional Cancer Registries (2025). Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022. Cancer Research and Treatment, 57(2), 312-330. https://doi.org/10.4143/crt.2025.264
Vancouver
Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022. Cancer Research and Treatment. 2025;57(2):312-330. doi:10.4143/crt.2025.264
BibTeX
@article{Park2025,
author = {Park, Eun Hye and Jung, Kyu-Won and Park, Nam Ju and Kang, Mee Joo and Yun, E Hwa and Kim, Hye-Jin and Kim, Jeong-Eun and Kong, Hyun-Joo and Choi, Kui Son and Yang, Han-Kwang and Community of Population-Based Regional Cancer Registries, Community of Population-Based Regional Cancer Registries},
title = {Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022},
journal = {Cancer Research and Treatment},
year = {2025},
volume = {57},
number = {2},
pages = {312--330},
doi = {10.4143/crt.2025.264}
}
EUVIMED